Who is sponsoring NCT04042272?

NCT04042272 is sponsored by Akdeniz University.

What drugs are being tested in NCT04042272?

Interventions in NCT04042272: S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP).

What condition does NCT04042272 study?

NCT04042272 studies Kidney Transplant; Complications, Neurologic Manifestations, Uremic Encephalopathy.

Is NCT04042272 still recruiting?

NCT04042272 is currently completed. Last updated 28 April 2021.

Last reviewed 2021-04-28 · How we verify

NCT04042272

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of s100β, NSE and GFAP Levels in Renal Transplantation

Completed Last updated 28 April 2021

What this trial tests

trial testing S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) in Kidney Transplant; Complications in 80 participants. Completed in 15 January 2021.

Timeline

15 August 2019

Primary endpoint
15 December 2020

15 January 2021

Quick facts

Lead sponsor	Akdeniz University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	80
Start date	15 August 2019
Primary completion	15 December 2020
Estimated completion	15 January 2021
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)

Conditions studied

Kidney Transplant; Complications — all drugs for Kidney Transplant; Complications →
Neurologic Manifestations — all drugs for Neurologic Manifestations →
Uremic Encephalopathy — all drugs for Uremic Encephalopathy →

Sponsor

Akdeniz University

Who can join

18 and older, any sex, with Kidney Transplant; Complications or Neurologic Manifestations. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Uremic encephalopathy is an organic brain disorder may be frequently seen in patients with acute or chronic renal failure. Certain neurological symptoms can be found under clinical glomerular filtration rate of 15 ml/minutes. The above mentioned neurological disorders can be due to uremic toxins as well as many other reasons such as metabolic and hemodynamic disturbances, inflammation, or oxidative stress. Most frequent symptoms are impaired consciousness, lethargy, cranial nerve involvement, nystagmus, dysarthria, and even coma and death. Brain tissue may receive damage and some secondary biomarkers may appear in case BUN (Blood Urea Nitrogen) level is \>175 mg/dl together with neuroinflammation. Although hemodialysis is a temporary solution in terms of treatment, these symptoms may be reversible in the long-run with organ transplantation. A rigorous neurological assessment before transplantation is important for identifying the severity and distribution of the neurological disorder as well as defining the abnormalities that are responding to the current treatments and foreseeing potential postoperative prognosis. S100β is excreted by astrocytes in brain damage cases. S100β level rises when brain damage starts, thus it may be used in the prognosis of brain damage in its early period. Neuron-specific enolase (NSE) functions as intracytoplasmic enzyme and serum level rises in neuron damage. Glial fibrillary acidic protein (GFAP), on the other hand, is the intermediary filament cytoskeleton protein found in astrocytes. It has the same root structure with S100β. The purpose of this study is to assess neurological damage by looking at the levels of S100β, NSE and GFAP in patients who underwent kidney transplantation and to analyze the impacts on the prognosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Kidney Transplant; Complications

Currently open trials in the same condition.

NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT06958796 — Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) · Phase 4 · recruiting
NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
NCT07033858 — Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation · NA · recruiting
NCT05782543 — Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion · NA · recruiting

Other Akdeniz University trials

Trials by the same sponsor.

NCT07581132 — Investigation of the Effect of Structured Energy Conservation Techniques Training on COPD Patients · NA · not yet recruiting
NCT07469345 — Bruxism, Pelvic Pain, Erectile Dysfunction, and Anxiety in Young Adult Men · enrolling by invitation
NCT07507279 — Technology-based Hand Rehabilitation in Older People · NA · not yet recruiting
NCT07437924 — Bruxism and Pelvic Floor Dysfunction in Young Women · enrolling by invitation
NCT07497308 — GDF-15 and Early Outcomes After LVAD Implantation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04042272 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Akdeniz University
Last refreshed: 28 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04042272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing